Headline: CPT code 82731 enables semiquantitative fetal fibronectin testing for preterm birth risk assessment

Lead: CPT code 82731 identifies the technical laboratory procedure that measures fetal fibronectin levels in cervicovaginal secretions using a semiquantitative method. This diagnostic assay informs clinical assessment of preterm birth risk and guides perinatal management decisions.

CPT code 82731 captures the laboratory-based, technical component of a fetal fibronectin assay. Nationally, standardized reporting of this code supports consistency in perinatal risk stratification and laboratory billing for obstetric providers and diagnostic labs. Payors commonly included in national analyses are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find: an explanation of the clinical purpose of the assay, the typical laboratory setting and service type, and the contexts in which semiquantitative fetal fibronectin results are used in obstetric risk assessment. The publication summarizes common billing pathways, relevant modifiers when reported by payers, and benchmarking considerations for laboratory technical components. It also outlines clinical context that frames when this test is clinically relevant to prenatal care and preterm birth risk evaluation.

This summary is written for a national audience of clinicians, billing professionals, and policy analysts seeking a clear description of CPT code 82731 and its role in perinatal diagnostic testing.